• Latest Posts

Roche and Alnylam to work on RNAi therapeutic to treat hypertension

Korro Bio and Frequency Therapeutics to merge

In Depth 10 Jul 2023

“Ready-to-use” enzymatically produced cell-free synthetic DNA in mRNA manufacturing

Flamingo Therapeutics receives €1.7M to advance RNA-targeting oncology portfolio

FDA approval for Rznomics’ glioblastoma treatment trial

ADVERTISEMENT

SiSaf siRNA therapy gets FDA designations to treat autosomal dominant osteopetrosis

Exothera partners with Quantoom and launches DNA business unit

Patients with asthma and other inflammatory lung diseases can be treated ‘in a fundamentally new way’

LincRNA discovery could lead to targeted treatments

RNA-based nanodrugs cause cancer cells to collapse – 80% survival rate for ovarian cancer in lab models

Intracellular drug delivery startup Vitarka Therapeutics raises £1.27M

ADVERTISEMENT